Tessa Mullins, DO
Dermatology · Lexington, KYNPI 1912439043
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 364 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 33.0% of the total. Reporting peaked in 2024 at $2,868 and has fallen 64.6% since, to $1,016 in 2025.
Across 364 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$961
- Regeneron Healthcare Solutions, Inc.$487
- Sanofi$475
- E.r. Squibb & Sons, L.L.C.$446
- Hill Dermaceuticals, Inc.$423
- plus $3K from 17 others
What the payments were for
- Food & beverage$7,85794%
- Education$5306%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 126 | $2,772 |
| Johnson & Johnson | 53 | $961 |
| Regeneron Healthcare Solutions, Inc. | 17 | $487 |
| Sanofi | 18 | $475 |
| E.r. Squibb & Sons, L.L.C. | 20 | $446 |
| Hill Dermaceuticals, Inc. | 1 | $423 |
| Pfizer | 29 | $411 |
| Sun Pharmaceutical Industries Inc. | 12 | $352 |
| Incyte Corporation | 13 | $292 |
| Novartis | 12 | $277 |
| UCB, Inc. | 9 | $274 |
| Amgen | 14 | $248 |
| Lilly USA, LLC | 12 | $227 |
| Boehringer Ingelheim | 8 | $216 |
| Genentech USA, Inc. | 2 | $133 |
| LEO Pharma Inc. | 6 | $133 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Galderma Laboratories, L.p. | 4 | $70 |
| Arcutis Biotherapeutics, Inc. | 2 | $35 |
| Dermavant Sciences, Inc. | 2 | $32 |
| Organogenesis Inc. | 1 | $26 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $14 |
| Kerecis Limited | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,387 in reported general payments places this provider in the 70th percentile of 128 dermatology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 72 | $338,728 |
| TremfyaGuselkumab | 11 | $159,530 |
| Humira(Cf) PenAdalimumab | 12 | $85,148 |
| Clobetasol Propionate | 188 | $5,483 |
| Ketoconazole | 166 | $2,219 |
| Gentamicin Sulfate | 54 | $2,148 |
| Tacrolimus | 12 | $2,072 |
| Clindamycin Phosphate | 47 | $2,020 |
| Triamcinolone Acetonide | 125 | $1,247 |
| Doxycycline Hyclate | 65 | $1,051 |
| Hydroxychloroquine Sulfate | 44 | $955 |
| Tretinoin | 12 | $844 |
| Metronidazole | 19 | $813 |
| Ciclopirox | 11 | $424 |
| Nystatin | 24 | $387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $961 | $159,53011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 128 dermatology providers in Kentucky.
Other dermatology in Lexington
- James WhartonLexington$1.2M
- Andrea WaldmanLexington$33K
- Dana BlackLexington$16K
- Jonathan KeelingLexington$13K
- Gerald ElliottLexington$12K
- Tandy RepassLexington$9K
- Joseph BarkLexington$8K
- Erika MusicLexington$7K
- Donna RothLexington$5K
- James LagrewLexington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.